Search results
Results From The WOW.Com Content Network
Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q2 2024 Earnings Call Aug 08, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
Inovio Pharmaceuticals Inc (NASDAQ:INO) reported its latest quarterly earnings results after the bell Wednesday, with revenue and earnings rising year-over-year. The pharmaceutical company ...
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading. Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
Inovio Pharmaceuticals Inc (NASDAQ: INO) shareholders are suing the company in U.S. District Court alleging the vaccine maker misled investors by saying it came up with a coronavirus vaccine ...
[7] [18] Inovio is in competition to develop a coronavirus vaccine with numerous other companies, which were conducting preclinical or early-stage human research on more than 170 vaccine candidates, as of late June. [5] In April 2020, Inovio began a Phase I trial of the COVID-19 vaccine candidate, INO-4800. [19]
Inovio Pharmaceuticals (INO) soared 5% in Tuesday’s after-market trading after the company announced positive interim data from a Phase 1/2a trial of DNA vaccine INO-4700 for MERS coronavirus ...
On 26 August 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil. [10] On 26 October 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history.